Katalyst Diagnostics has been acquired by Cruinn Diagnostics

September 2026 — Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.

Katalyst Diagnostics is a UK-based point-of-care diagnostics business specializing in premium and innovative diagnostic solutions for healthcare organizations and clinical professionals. The company provides access to advanced point-of-care technologies in areas including hematology, clinical chemistry and antipsychotic drug monitoring. Based in London, Katalyst Diagnostics supports NHS and other healthcare organizations across the UK and Ireland, with solutions designed to deliver rapid, laboratory-quality results at the point of care. Its portfolio includes HemoScreen, Piccolo Xpress and MyCare INSITE, supported by specialist expertise in diagnostics, training, logistics and customer service.

Cruinn Diagnostics is an Irish-owned company established in 1998 and one of Ireland’s leading distributors of laboratory and diagnostic products. The company supplies clinical diagnostics, laboratory equipment and consumables, life sciences, pharmaceutical and food testing solutions, point-of-care diagnostics, ultrasound systems and calibration and testing services. Working with leading international manufacturers, Cruinn Diagnostics supports hospitals, independent laboratories, pharmaceutical and life sciences companies, universities, research organizations and other specialist customers across Ireland. Its comprehensive portfolio covers clinical chemistry, microbiology, immunoassay, molecular diagnostics and laboratory equipment and consumables, supported by dedicated product specialists and customer service teams.

Our role in the transaction

Oaklins S&W, one of Oaklins’ member firms in the UK, acted as the sell-side M&A advisor to the shareholders of Katalyst Diagnostics. The transaction demonstrates the team’s strong track record in healthcare and life sciences, supporting founder-led and privately owned businesses through complex transactions in regulated end markets.